

SEC /240/2021

July 22, 2021

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400001.
Scrip code: 542867

National Stock Exchange of India Ltd.,
Exchange plaza, 5th floor,
Bandra-kurla Complex,
Bandra (E), Mumbai 400051.
Symbol: CSBBANK

Dear Sir/Madam,

Submission of Newspaper publication of the Intimation of 100th Annual General Meeting of the Bank, e-voting and book closure

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation of our letter no. SEC/207/2021 dated July 06, 2021, please find enclosed herewith the clippings of the Intimation of Hundredth (100th) Annual General Meeting of the Bank, e-voting and book closure published in today's Newspaper (July 22, 2021) viz. Business Standard (English) and Deepika (Malayalam).

This intimation is also made available on the website of the Bank at www.csb.co.in.

Kindly take the same on records.

Thanking You.

Yours faithfully,

**Sijo Varghese
Company Secretary**

AS COVID CLAIMS SPIKE IN Q1...

Insurers' provision pool gets bigger

Claims in 2nd wave were 3-4 times the volume seen in first wave, says an insurer

SUBRATA PANDA
Mumbai, 21 July

The impact of the second wave, which saw higher fatalities than the first one, coupled with elevated levels of claims that life insurers have received in Q1, resulted in insurers increasing their provision pool. This is over and above the amount they had set aside at the beginning of the financial year.

Insurers, in the April-June quarter of FY22, have seen a huge spike in death claims due to Covid. And, experts said, Covid death claims in Q1 are higher than the cumulative Covid-related death claims in the entire FY21.

The overall claims burden has also increased due to the mounting Covid claims, they said.

Two of the largest private-sector life insurers — ICICI Prudential and HDFC Life — which came out with their first-quarter numbers, have set aside more provisions, anticipating higher Covid-related death claims in the next three months.

HDFC Life has set up an extra



SHORING UP RESERVES

- Life insurers have seen higher Covid-related death claims in Q1
- They expect claims to remain at an elevated level for the next 2-3 months
- Hence, they have increased their provisions against such liabilities
- Insurers had set aside provisions after Q4FY21, anticipating higher claims
- But, they had to revise it due to a steep rise in claims following higher fatalities
- HDFC Life has created a reserve of ₹700 cr
- ICICI Prudential Life has increased its provisions to ₹500 crore

reserve of ₹700 crore to service the additional claims. Similarly, ICICI Prudential has increased its provisions to ₹500 crore at the end of the April-June quarter from ₹332 crore, which it had set aside after Q4 of FY21.

According to HDFC Life, in the quarter gone by, it witnessed a steep rise in death claims with peak claims in the "second wave" at around 3-4 times the peak claim volumes in the first wave.

"We paid over 70,000 claims in Q1. The gross and net claims provided for amounted to ₹1,598 crore and ₹956 crore, respectively," the company said.

ICICI Prudential paid almost ₹500 crore as Covid-related death claims in Q1 of FY22, which is almost 2.5 times the amount it paid out for Covid-related death claims in FY21.

Satyan Jambunathan, chief financial officer (CFO), ICICI Prudential, told Business Standard, "For Q1 of FY22, claims due to Covid-19 were to the tune of ₹500 crore. Given the severity of the situation, we thought it prudent to revise the provision amount to ₹500 crore. We believe as long as Covid-19 related claims remain within the boundaries of ₹1,000 crore, that is around 5 times that of last fiscal, we will be fully provided for. Given the circumstances, claims come in with a lag. So, over and above the provisions for Covid-19 related claims, we are carrying an additional ₹380 crore of provisions for delayed claims not related to the pandemic."

Insurers had anticipated this situation and had set aside higher provisions at the end of Q4 of FY21. HDFC Life had set aside ₹165 crore, which is four times higher than what it had set aside in FY21. SBI Life had set aside ₹180 crore.

But, given the fact that the second

wave saw an alarming rise in fatalities due to Covid, the firms had to revise their provision pool, which dented profits of two of the three listed players.

SBI Life has not come out with its quarterly result. HDFC Life's net profit in Q1 of FY22 was down 33 per cent over the same period last year and ICICI Prudential reported a net loss during Q1.

Although the second wave turned out to be much worse than what the industry had anticipated, insurers, so far, have not figured out if they would need more provisions in case a third wave occurs.

Commenting on the possibility of a further revision in provisions, Jambunathan said, "...in our target market, we think vaccination progress has been quite robust and rapid. We believe the rest of the year will be much better compared to the first quarter."

Rushabh Gandhi, deputy chief executive officer (CEO), IndiaFirst Life Insurance, said, "We have seen a substantial increase in Covid claims in Q1 of FY22 compared to FY21 and hold adequate reserves to meet the current increase in claims. We believe that the worst is behind us. With the vaccination drive in full swing, we believe it is early to predict the claim trends conclusively, and thus, the consequent provisioning."

Bird flu death spells trouble for ₹90,000-cr poultry sector



SANJEEB MUKHERJEE &
RUCHIKA CHITRAVANSHI
New Delhi, 21 July

to spread from chickens but other birds such as ducks and crow are also carriers of the virus.

The National Centre for Disease Control (NCDC) has alerted all its centres across the country under the Integrated Disease Surveillance Programme (IDSP) to look for suspected cases.

The IDSP State Surveillance Unit of Haryana has initiated an epidemiological investigation into the first documented human case of bird flu. The health ministry said close contacts of the deceased were under surveillance for any symptoms. The animal husbandry department has not found any suspected cases of bird flu in the area and has enhanced surveillance in a 10-km zone as a precautionary measure.

"Epidemiological investigation by NCDC, involving animal husbandry department and the state government surveillance unit, is underway and appropriate public health measures have been instituted," the health ministry said.

An AIIMS source had said the boy was admitted to the hospital on July 2 with pneumonia and leukemia. He died on July 12.

"His samples tested negative for Covid-19. It came out positive for influenza but was non-typable. It was sent to National Institute of Virology, Pune, where they confirmed it to be positive for H5N1 avian influenza," news agency PTI reported quoting an unnamed source.

Vikas Maurya, director and head of department — pulmonology, Fortis Hospital said human-to-human transmission of bird flu is rare and not fast. "But, exposure to infected birds (such as in the poultry industry) can cause this disease. It is a respiratory disease like influenza and if it is severe it can even cause death," Maurya said.

RBI gives IDFC nod to exit IDFC FIRST Bank

ANUP ROY
Mumbai, 21 July

IDFC said on Wednesday that it had received permission from the Reserve Bank of India (RBI) to exit the IDFC FIRST Bank as promoters.

IDFC is the owner of the holding company IDFC Financial Holding Company, which in turn holds 36.56 per cent stake in the bank. IDFC's exit from the bank will indicate that the holding company could reverse merge with the bank, in line with what two small finance banks recently announced. If the holding company merges with the bank, then IDFC may have to sell its mutual funds business as well, analysts say.

The bank management was not immediately available for comment on the development.

IDFC announced receiving the RBI's approval in a notification to the exchanges. The 36.56 per cent holding of IDFC is valued at ₹11,618 crore at the current market price.



IDFC Bank received the licence from the RBI in 2014, and was floated in 2015

IDFC Bank received the licence from the RBI in 2014, and was floated in 2015. So, the five-year period came to an end in October 2020. The bank merged with Capital FIRST in 2018 to become IDFC FIRST Bank.

The initial licensing condition to IDFC was that the promoters must have a minimum of 40 per cent stake locked in for five years.

Recently, two small finance banks — Ujjivan SFB and Equitas SFB — said they would reverse merge their respective holding companies with themselves as the five-year lock-in period expired for the promoter holding companies.

However, IDFC said in its notification that it received permission to exit the bank altogether.

FROM PAGE 1

'Demand-supply mismatch not a concern, working towards it'

During the last three to four quarters, demand for digital transformation has been phenomenal. Can this be sustained and how are you making sure that Infosys is able to harness this growth?

Tech is becoming pervasive. Today what we are seeing is not just a wave, but now everything is becoming tech driven. We are in a very early cycle of this digital wave from a worldwide perspective. Take any statistics, the percentage of work being done digitally is growing but it is yet to gain significance. That gives a lot of traction for medium and long-term growth perspective. For Infosys particularly, the way we can keep current with clients is to keep coming up with innovative platforms like Cobalt. We are building something similar in data analytics, we are strong in AI, automation etc. Innovation will be key to benefit multifold from this tech growth.

How significant will be M&A when Infosys is creating platforms such as Cobalt?

It will be a combination. Internally we built a digital pentagon that maps market spaces in the digital business. We will be seeing more asset acquisitions. But the key is not just acquisition. We need to integrate these into Infosys and make sure all the elements of the company come together to create what clients want. With Cobalt we have managed to bring

all the dispersed aspects together coherently and that is why we are seeing some of our success.

How much of a concern is the current demand-supply mismatch?


We have been increasing fresher hiring from campuses. We were able to add 8,000 people in Q1 because we have a very attractive proposition for those joining Infosys. It is not a concern and we are working towards it.

With work from anywhere, do you see the need for sending employees onsite or to other geographies coming down significantly?

The aspirations of a new college graduate are very different. They want projects that involve new tech, or from newer industries and also tech that excite them. We fortunately have all of this. Also we have teams across the globe which are mixed. Yes, we are doing recruitments in these geographies but there is opportunity for several of them to get international exposure.

How significant is India as a market for Infosys and how soon would the IT portal issue be resolved?

We are extremely proud of the work we are doing in India. It has been a combination of central, and state government and private enterprise. India is still a small market but whatever we do, we do it with full



focus. The potential in India is enormous, because of the way the country is moving towards digitization.

The IT project had some points that needed attention at the start and several of these issues have been attended to. We are working collaboratively with the IT department as well as the CA associations and others. Many of the issues have been addressed and my feeling is that the inputs have been provided and things are progressing well.

Sputnik V...

Apart from India, Sputnik V has production bases in South Korea, Brazil, China, Saudi Arabia, and Turkey. Most of these are contract manufacturing facilities.

In April, Russian pharmaceutical firm R-Pharm said it expected to produce up to 8-10 million doses a month of the Sputnik V vaccine at its German plant in Bavaria. Reports suggest Germany is gearing up to start bilateral negotiations with Russia to obtain supplies of the vaccine, though a final decision would depend on approval by the European Medicines Agency (EMA). Despite the global tie-ups, Sputnik V production has not picked up. According to Reuters, Russia had produced only 33 million doses of Sputnik V as of May. This is far lesser than the hundreds of millions of doses that Pfizer and AstraZeneca are making every month.

An Indian contract manufacturer said, "The process to make Sputnik V is complex and time consuming. It takes about two months to make the product, which is then compared with the reference product. If it does not match, then we have to throw away the production." The person added that the process was made doubly complex because of the fact that Sputnik V used two different vectors in its two doses. Russia is looking to develop both manufacturing bases and markets for its Covid-19 vaccine outside the country, as not many Russians have shown interest in Sputnik V, which claims to have an efficacy of 97.6%.

